- Price
- $46.41
- Day
- +3.48%
- Mkt Cap
- $3.70B
- 52W Range
- $23.79 – $60.91
- Volume
- 1.94M
- Beta
- 1.93
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Read full article
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Read full article
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Read full article
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
Read full article
First Trust Advisors LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 64.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,117,046 shares of the biotechnology company's stock after acquiring an additional 833,543 shares during the
Read full article
Fifth Third Bancorp boosted its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 10,285.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,549 shares of the biotechnology company's stock after purchasing an additional 52,043 shares during the period. Fifth Third
Read full article
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Read full article
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,045,047 shares of the biotechnology company's stock after selling 212,851 shares during the quarter. Amova
Read full article
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Read full article
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Read full article
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Read full article